{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:26:21Z","timestamp":1789928781503,"version":"4.0.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe a case of severe accidental cyanide poisoning following a single ingestion of amygdalin with therapeutic intent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 68-year-old patient with cancer presented to the emergency department shortly after her first dose (3 g) of amygdalin with a reduced Glasgow Coma Score, seizures, and severe lactic acidosis requiring intubation and ventilation. The patient also ingested 4800 mg of vitamin C per day. She responded rapidly to hydroxocobalamin treatment. The adverse drug reaction was rated probable on the Naranjo probability scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Amygdalin and laetrile (a synthetic form of amygdalin) are commonly used as complementary or alternative medicine (CAM) for the treatment of cancer. Vitamin C is known to increase the in vitro conversion of amygdalin to cyanide and reduce body stores of cysteine, which is used to detoxify cyanide. Amygdalin has been used for decades by patients with cancer who are seeking alternative therapies, and severe reactions have not been reported with this dose. An interaction with vitamin C is a plausible explanation for this life-threatening response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>This case highlights the fact that CAMs can produce life-threatening toxicity. This case also adds a further note of caution, namely, the potential for serious interactions between CAMs, particularly where there is no tradition of concomitant use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1e634","type":"journal-article","created":{"date-parts":[[2005,7,13]],"date-time":"2005-07-13T08:09:45Z","timestamp":1121242185000},"page":"1566-1569","source":"Crossref","is-referenced-by-count":80,"title":["Life-Threatening Interaction Between Complementary Medicines: Cyanide Toxicity Following Ingestion of Amygdalin and Vitamin C"],"prefix":"10.1177","volume":"39","author":[{"given":"Jonathan","family":"Bromley","sequence":"first","affiliation":[{"name":"Jonathan Bromley MBChB, Toxicology Registrar, Department of Clinical Pharmacology and Toxicology, The Canberra Hospital, Garran, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett GM","family":"Hughes","sequence":"additional","affiliation":[{"name":"Brett GM Hughes BSc (Med) MBBS (Hons), Medical Oncology Registrar, Department of Medical Oncology, The Canberra Hospital David CS Leong MBBS FRACP, Consultant Medical Oncologist, Department of Medical Oncology, The Canberra Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David CS","family":"Leong","sequence":"additional","affiliation":[{"name":"David CS Leong MBBS FRACP, Consultant Medical Oncologist, Department of Medical Oncology, The Canberra Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Buckley","sequence":"additional","affiliation":[{"name":"Nicholas A Buckley MD FRACP, Consultant Toxicologist and Clinical Pharmacologist, Department of Clinical Pharmacology and Toxicology, The Canberra Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"bibr1-aph.1E634","unstructured":"Buckley NA, Dawson AH, Whyte IM. Hypertox. Assessment and treatment of poisoning. www.hypertox.com (accessed 2005 Mar 15)."},{"key":"bibr2-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200209000-00015"},{"key":"bibr3-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr4-aph.1E634","first-page":"1155","volume-title":"Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning","author":"Erdman WA","year":"2003","edition":"3"},{"key":"bibr5-aph.1E634","volume-title":"Cyanogenic glycosides (WHO Food Additives Series 30)","author":"Speijers G"},{"key":"bibr6-aph.1E634","first-page":"330","volume":"232","author":"Chander RF","year":"1984","journal-title":"Pharmaceut J"},{"key":"bibr7-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198201283060403"},{"key":"bibr8-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03310310033018"},{"key":"bibr9-aph.1E634","unstructured":"Winter P. Laetrile alternative cancer treatment comparison. http:\/\/alternativecancer.us\/laetrile.htm (accessed 2005 Mar 3)."},{"key":"bibr10-aph.1E634","unstructured":"Clark J. All natural cancer therapy\u2014vitamin B\n                      17\n                      suggested dosage. http:\/\/home.bluegrass.net\/\u223cjclark\/print_dosage.htm (accessed 2005 Mar 3)."},{"key":"bibr11-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(79)90047-1"},{"key":"bibr12-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/32.5.1121"},{"key":"bibr13-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1139\/y83-203"},{"key":"bibr14-aph.1E634","unstructured":"Wilson B. Quackwatch\u2014the rise and fall of laetrile. www.quackwatch.org\/01QuackeryRelatedTopics\/Cancer\/laetrile.html (accessed 2005 Mar 3)."},{"key":"bibr15-aph.1E634","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.41.3.187"},{"key":"bibr16-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.18.1569"},{"key":"bibr17-aph.1E634","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06457-0"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1E634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:40Z","timestamp":1777374640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1E634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1345\/aph.1E634"],"URL":"https:\/\/doi.org\/10.1345\/aph.1e634","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}